Black Friday saleUp to 70% OFF
Poseida Therapeutics, Inc.Poseida Therapeutics, Inc.Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

PSTX chart


Full chart

PSTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪278.75 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.63 USD
Net income (FY)
‪−123.43 M‬ USD
Revenue (FY)
‪64.70 M‬ USD
Shares float
‪67.79 M‬
Beta (1Y)
2.81

Employees


Employees (FY)
330
Change (1Y)
+16 +5.10%
Revenue / Employee (1Y)
‪196.07 K‬ USD
Net income / Employee (1Y)
‪−374.03 K‬ USD

About Poseida Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Kristin Yarema
Website
poseida.com
Headquarters
San Diego
Founded
2014
FIGI
BBG00BNTZ9H0
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

PSTX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of PSTX is 9.38 USD — it has increased by 4.76% in the past 24 hours. Watch Poseida Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Poseida Therapeutics, Inc. stocks are traded under the ticker PSTX.
PSTX stock has risen by 3.62% compared to the previous week, the month change is a 18.18% rise, over the last year Poseida Therapeutics, Inc. has showed a 235.00% increase.
We've gathered analysts' opinions on Poseida Therapeutics, Inc. future price: according to them, PSTX price has a max estimate of 10.00 USD and a min estimate of 9.00 USD. Watch PSTX chart and read a more detailed Poseida Therapeutics, Inc. stock forecast: see what analysts think of Poseida Therapeutics, Inc. and suggest that you do with its stocks.
PSTX reached its all-time high on Jul 17, 2020 with the price of 17.62 USD, and its all-time low was 1.54 USD and was reached on Jun 29, 2023. View more price dynamics on PSTX chart.
See other stocks reaching their highest and lowest prices.
PSTX stock is 70.81% volatile and has beta coefficient of 2.81. Track Poseida Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Poseida Therapeutics, Inc. there?
Today Poseida Therapeutics, Inc. has the market capitalization of ‪278.75 M‬, it has decreased by −1.81% over the last week.
Yes, you can track Poseida Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Poseida Therapeutics, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
PSTX earnings for the last quarter are 0.21 USD per share, whereas the estimation was −0.42 USD resulting in a 150.30% surprise. The estimated earnings for the next quarter are −0.33 USD per share. See more details about Poseida Therapeutics, Inc. earnings.
Poseida Therapeutics, Inc. revenue for the last quarter amounts to ‪71.75 M‬ USD, despite the estimated figure of ‪16.25 M‬ USD. In the next quarter, revenue is expected to reach ‪21.25 M‬ USD.
PSTX net income for the last quarter is ‪20.23 M‬ USD, while the quarter before that showed ‪−31.37 M‬ USD of net income which accounts for 164.50% change. Track more Poseida Therapeutics, Inc. financial stats to get the full picture.
No, PSTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 27, 2024, the company has 330.00 employees. See our rating of the largest employees — is Poseida Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Poseida Therapeutics, Inc. EBITDA is ‪−57.03 M‬ USD, and current EBITDA margin is −294.41%. See more stats in Poseida Therapeutics, Inc. financial statements.
Like other stocks, PSTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Poseida Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Poseida Therapeutics, Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Poseida Therapeutics, Inc. stock shows the strong buy signal. See more of Poseida Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.